Allarity Therapeutics (ALLR) Outlines Company’s 2024 Progress and Objectives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
July 22, 2024 6:30 AM EDTÂ
Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATM
Cap Table Successfully Cleaned Up
Allaritys Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit
Boston (July 22, 2024)Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Companys... More
